Acetaminophen Tablet Extended Release side effects: what 253,493 FDA adverse event reports show
Drug class
Not stated in label
Who reports
253,493 reports · 87% serious · 49,975 with death outcome · 62% female
Used for
Acetaminophen injection is indicated for • the management of mild to moderate pain in adult and pediatric patients 2 years and older • the management of moderate to severe pain with adjunctive opioid analgesics in adult and pediatric patients 2 years and older • the reduction of fever in adult and pediatric patients.
What it is
Paracetamol is a member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.
Boxed warning
RISK OF MEDICATION ERRORS AND HEPATOTOXICITY Take care when prescribing, preparing, and administering acetaminophen injection to avoid dosing errors which could result in accidental overdose and death. In particular,.
Causality screen of the 40 strongest signals
What the badges mean
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,162 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Pyroglutamic acidosis | 287 | 262.8 207.0–333.7ROR 263.1 · calibrated p 6e-11 ✓ | 62.2 EB05 56.4 · IC025 +5.6 3/3 methods agree | Not in label — unassessed | serious n=286 · 100% clinician | no trial arm names this drug |
| Vaginal flatulence | 223 | 227.5 176.0–294.0ROR 227.7 · calibrated p 2e-10 ✓ | 60.0 EB05 53.6 · IC025 +5.5 3/3 methods agree | Not in label — unassessed | serious n=223 · ♀ 100% (drug 62%) · 100% clinician | no trial arm names this drug |
| Appendicolith | 276 | 224.7 178.6–282.7ROR 224.9 · calibrated p 2e-10 ✓ | 59.8 EB05 54.1 · IC025 +5.6 3/3 methods agree | Not in label — unassessed | serious n=276 · ♀ 0% (drug 62%) · 100% clinician | no trial arm names this drug |
| Anti-cyclic citrullinated peptide antibody | 416 | 138.0 117.8–161.6ROR 138.2 · calibrated p 1e-8 ✓ | 51.4 EB05 47.4 · IC025 +5.4 3/3 methods agree | Lab value / disease marker | serious n=416 · ♀ 100% (drug 62%) · 100% clinician | no trial arm names this drug |
| Anti-cyclic citrullinated peptide antibody positive | 4,399 | 135.5 129.1–142.2ROR 137.9 · calibrated p 9e-9 ✓ | 51.2 EB05 49.9 · IC025 +5.6 3/3 methods agree | Lab value / disease marker | serious PRR 33.8 · ♀ 100% (drug 62%) · 94% clinician | no trial arm names this drug |
| Rheumatic fever | 2,684 | 132.9 125.0–141.3ROR 134.3 · calibrated p 1e-8 ✓ | 50.8 EB05 49.2 · IC025 +5.6 3/3 methods agree | Not in label — unassessed | serious n=2,683 · ♀ 100% (drug 62%) · 94% clinician | no trial arm names this drug |
| Deep vein thrombosis postoperative | 1,180 | 125.8 114.8–137.8ROR 126.4 · calibrated p 2e-8 ✓ | 49.7 EB05 47.4 · IC025 +5.5 3/3 methods agree | Not in label — unassessed | serious n=1,180 · ♀ 100% (drug 62%) · 93% clinician | no trial arm names this drug |
| Swollen joint count increased | 1,875 | 125.5 116.8–134.9ROR 126.4 · calibrated p 2e-8 ✓ | 49.7 EB05 47.8 · IC025 +5.5 3/3 methods agree | Lab value / disease marker | serious n=1,873 · ♀ 100% (drug 62%) · 96% clinician | no trial arm names this drug |
| Duodenal ulcer perforation | 4,404 | 124.9 119.2–130.9ROR 127.1 · calibrated p 2e-8 ✓ | 49.6 EB05 48.4 · IC025 +5.6 3/3 methods agree | Not in label — unassessed | serious PRR 32.6 · ♀ 100% (drug 62%) · 94% clinician | no trial arm names this drug |
| C-reactive protein | 532 | 117.8 103.1–134.6ROR 118.0 · calibrated p 4e-8 ✓ | 48.4 EB05 45.0 · IC025 +5.4 3/3 methods agree | Lab value / disease marker | serious n=532 · ♀ 100% (drug 62%) · 100% clinician | no trial arm names this drug |
| Lupus vulgaris | 689 | 114.3 101.7–128.3ROR 114.6 · calibrated p 4e-8 ✓ | 47.8 EB05 44.9 · IC025 +5.4 3/3 methods agree | Not in label — unassessed | serious n=689 · ♀ 100% (drug 62%) · 100% clinician | no trial arm names this drug |
| Exposure to toxic agent | 1,696 | 92.1 85.9–98.7ROR 92.7 · calibrated p 2e-7 ✓ | 43.5 EB05 41.8 · IC025 +5.3 3/3 methods agree | Not in label — unassessed | serious n=1,690 · 100% clinician | no trial arm names this drug |
| Facet joint syndrome | 1,632 | 88.9 82.8–95.3ROR 89.4 · calibrated p 3e-7 ✓ | 42.8 EB05 41.1 · IC025 +5.3 3/3 methods agree | Not in label — unassessed | serious n=1,631 · ♀ 100% (drug 62%) · 95% clinician | no trial arm names this drug |
| Blood pressure diastolic abnormal | 1,292 | 83.6 77.4–90.4ROR 84.1 · calibrated p 4e-7 ✓ | 41.5 EB05 39.7 · IC025 +5.3 3/3 methods agree | Lab value / disease marker | serious n=1,259 · 90% clinician | no trial arm names this drug |
| Blood pressure systolic abnormal | 1,191 | 75.8 70.0–82.0ROR 76.1 · calibrated p 8e-7 ✓ | 39.5 EB05 37.7 · IC025 +5.2 3/3 methods agree | Lab value / disease marker | serious n=1,156 · 91% clinician | no trial arm names this drug |
| Rheumatoid factor positive | 2,748 | 75.2 71.4–79.1ROR 76.0 · calibrated p 8e-7 ✓ | 39.4 EB05 38.1 · IC025 +5.2 3/3 methods agree | Lab value / disease marker | serious n=2,747 · ♀ 100% (drug 62%) · 95% clinician | no trial arm names this drug |
| Muscle injury | 3,742 | 69.2 66.2–72.3ROR 70.2 · calibrated p 1e-6 ✓ | 37.7 EB05 36.7 · IC025 +5.2 3/3 methods agree | Labeled (related wording) related wording | serious PRR 26.9 · ♀ 100% (drug 62%) · 93% clinician | no trial arm names this drug |
| Helicobacter infection | 4,470 | 64.4 62.0–67.0ROR 65.6 · calibrated p 2e-6 ✓ | 36.2 EB05 35.4 · IC025 +5.1 3/3 methods agree | Not in label — unassessed | serious PRR 25.2 · ♀ 100% (drug 62%) · 93% clinician | no trial arm names this drug |
| Sleep disorder due to general medical condition, insomnia type | 2,774 | 62.4 59.4–65.6ROR 63.1 · calibrated p 3e-6 ✓ | 35.6 EB05 34.5 · IC025 +5.1 3/3 methods agree | Labeled (related wording) related wording | serious n=2,769 · ♀ 100% (drug 62%) · 93% clinician | no trial arm names this drug |
| Adjustment disorder with depressed mood | 857 | 61.0 55.8–66.6ROR 61.2 · calibrated p 4e-6 ✓ | 35.1 EB05 33.2 · IC025 +5.0 3/3 methods agree | Not in label — unassessed | serious n=856 · ♀ 100% (drug 62%) · 100% clinician | no trial arm names this drug |
| Folliculitis | 4,258 | 57.8 55.6–60.1ROR 58.8 · calibrated p 5e-6 ✓ | 34.1 EB05 33.2 · IC025 +5.0 3/3 methods agree | Not in label — unassessed | serious PRR 26.4 · ♀ 100% (drug 62%) · 93% clinician | no trial arm names this drug |
| Pemphigus | 4,971 | 54.9 53.0–56.9ROR 56.0 · calibrated p 7e-6 ✓ | 33.1 EB05 32.3 · IC025 +5.0 3/3 methods agree | Not in label — unassessed | serious PRR 21.9 · ♀ 99% (drug 62%) · 93% clinician | no trial arm names this drug |
| X-ray abnormal | 705 | 53.8 48.9–59.1ROR 53.9 · calibrated p 9e-6 ✓ | 32.6 EB05 30.6 · IC025 +4.9 3/3 methods agree | Lab value / disease marker | serious n=705 · ♀ 100% (drug 62%) · 100% clinician | no trial arm names this drug |
| Hand deformity | 5,080 | 52.3 50.5–54.1ROR 53.3 · calibrated p 9e-6 ✓ | 32.1 EB05 31.4 · IC025 +5.0 3/3 methods agree | Not in label — unassessed | serious PRR 23.0 · ♀ 100% (drug 62%) · 92% clinician | no trial arm names this drug |
| Subcutaneous drug absorption impaired | 211 | 52.0 43.7–61.8ROR 52.0 · calibrated p 1e-5 ✓ | 31.9 EB05 28.5 · IC025 +4.7 3/3 methods agree | Not in label — unassessed | serious n=204 · ♀ 100% (drug 62%) · 100% clinician | no trial arm names this drug |
| Dislocation of vertebra | 853 | 51.2 47.0–55.8ROR 51.4 · calibrated p 1e-5 ✓ | 31.7 EB05 29.9 · IC025 +4.8 3/3 methods agree | Not in label — unassessed | serious n=853 · ♀ 100% (drug 62%) · 94% clinician | no trial arm names this drug |
| Suspected suicide attempt | 206 | 46.9 39.5–55.7ROR 46.9 · calibrated p 2e-5 ✓ | 29.9 EB05 26.7 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | serious n=206 · ♀ 100% (drug 62%) · 100% clinician | no trial arm names this drug |
| Analgesic drug level increased | 585 | 46.6 42.1–51.6ROR 46.7 · calibrated p 2e-5 ✓ | 29.9 EB05 27.9 · IC025 +4.7 3/3 methods agree | Lab value / disease marker | serious n=585 · 100% clinician | no trial arm names this drug |
| Anion gap | 213 | 41.0 34.7–48.3ROR 41.0 · calibrated p 5e-5 ✓ | 27.4 EB05 24.5 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=212 · 100% clinician | no trial arm names this drug |
| Peripheral venous disease | 1,266 | 38.1 35.7–40.8ROR 38.3 · calibrated p 7e-5 ✓ | 26.2 EB05 25.0 · IC025 +4.6 3/3 methods agree | Labeled (related wording) related wording | serious n=1,265 · ♀ 100% (drug 62%) · 92% clinician | no trial arm names this drug |
| Retinitis | 517 | 36.8 33.2–40.9ROR 36.9 · calibrated p 9e-5 ✓ | 25.6 EB05 23.8 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=517 · ♀ 100% (drug 62%) · 100% clinician | no trial arm names this drug |
| Synovitis | 5,573 | 36.7 35.6–37.9ROR 37.5 · calibrated p 8e-5 ✓ | 25.5 EB05 25.0 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | serious PRR 17.6 · ♀ 98% (drug 62%) · 91% clinician | no trial arm names this drug |
| Pericarditis | 5,041 | 35.6 34.5–36.8ROR 36.3 · calibrated p 9e-5 ✓ | 25.0 EB05 24.4 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | serious PRR 16.6 · ♀ 98% (drug 62%) · 93% clinician | no trial arm names this drug |
| C-reactive protein abnormal | 1,839 | 33.0 31.3–34.9ROR 33.3 · calibrated p 1e-4 ✓ | 23.7 EB05 22.8 · IC025 +4.5 3/3 methods agree | Lab value / disease marker | serious n=1,836 · ♀ 100% (drug 62%) · 93% clinician | no trial arm names this drug |
| Sedation complication | 588 | 25.2 23.0–27.7ROR 25.3 · calibrated p 7e-4 ✓ | 19.4 EB05 18.1 · IC025 +4.1 3/3 methods agree | Reporting / coding artifact | serious n=585 · ♀ 100% (drug 62%) | no trial arm names this drug |
| Amaurosis fugax | 250 | 25.0 21.7–28.8ROR 25.0 · calibrated p 7e-4 ✓ | 19.3 EB05 17.4 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=250 · 100% clinician | no trial arm names this drug |
| Seronegative arthritis | 257 | 24.3 21.2–28.0ROR 24.4 · calibrated p 8e-4 ✓ | 18.9 EB05 17.0 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=257 · ♀ 100% (drug 62%) · 100% clinician | no trial arm names this drug |
| Infusion site discharge | 385 | 23.8 21.3–26.7ROR 23.8 · calibrated p 9e-4 ✓ | 18.6 EB05 17.1 · IC025 +4.0 3/3 methods agree | Labeled (related wording) related wording | serious n=312 · 100% consumer | no trial arm names this drug |
| Glossodynia (burning tongue/mouth pain) | 4,978 | 23.5 22.8–24.2ROR 23.9 · calibrated p 8e-4 ✓ | 18.4 EB05 18.0 · IC025 +4.2 3/3 methods agree | Labeled (related wording) related wording | serious PRR 17.4 · ♀ 100% (drug 62%) · 92% clinician | no trial arm names this drug |
| Porphyria acute | 288 | 21.6 19.0–24.6ROR 21.6 · calibrated p 0.001 ✓ | 17.2 EB05 15.6 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=287 · ♀ 100% (drug 62%) · 100% clinician | no trial arm names this drug |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Liver injury | 20,395 | 5.95.8–6.0 | signal |
| Suicidality | 13,609 | 4.84.7–4.9 | signal |
| Severe cutaneous reaction | 2,865 | 3.33.2–3.4 | signal |
| Interstitial lung disease | 3,322 | 2.92.8–3.0 | signal |
| Serious infection | 26,126 | 2.92.8–2.9 | signal |
| Neutropenia / agranulocytosis | 8,078 | 2.82.7–2.8 | signal |
| Hyponatraemia | 2,623 | 2.82.6–2.9 | signal |
| Kidney injury | 14,071 | 2.62.6–2.6 | signal |
| Anaphylaxis / angioedema | 3,732 | 2.52.4–2.6 | signal |
| Anaemia | 8,172 | 2.32.2–2.3 | signal |
| Gi bleeding | 4,781 | 2.22.1–2.3 | signal |
| Thrombocytopenia | 5,665 | 2.22.1–2.2 | signal |
| Rhabdomyolysis / myopathy | 2,061 | 2.12.0–2.2 | signal |
| Pancreatitis | 1,999 | 2.12.0–2.2 | raised |
| Fall / fracture | 9,271 | 2.02.0–2.1 | raised |
| Opportunistic infection | 3,173 | 1.91.9–2.0 | raised |
Trial evidence (ClinicalTrials.gov)
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Off label use (used outside approved label) | 23,028 | 2.2 2.2–2.3ROR 2.3 · calibrated p 0.880 | 2.2 EB05 2.2 · IC025 +1.1 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 1.9 · serious PRR 2.5 | no trial arm names this drug |
| Fatigue (tiredness) | 20,901 | 2.3 2.2–2.3ROR 2.4 · calibrated p 0.869 | 2.2 EB05 2.2 · IC025 +1.1 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 1.9 · serious PRR 2.5 | no trial arm names this drug |
| Drug ineffective (drug did not work) | 18,581 | 1.2 1.2–1.2ROR 1.2 · calibrated p 0.428 | 1.2 EB05 1.2 · IC025 +0.2 | Reporting / coding artifact | age-adj. PRR 1.3 · serious PRR 2.0 | no trial arm names this drug |
| Pain | 18,465 | 2.5 2.5–2.6ROR 2.6 · calibrated p 0.752 | 2.5 EB05 2.5 · IC025 +1.3 3/3 methods agree | Likely indication confounding term in indications; also in warnings | age-adj. PRR 2.5 · serious PRR 2.4 | no trial arm names this drug |
| Nausea | 18,164 | 1.9 1.9–2.0ROR 2.0 · calibrated p 0.942 | 1.9 EB05 1.9 · IC025 +0.9 | Labeled adverse reaction exact term | age-adj. PRR 1.7 · serious PRR 2.1 | no trial arm names this drug |
| Headache | 17,128 | 2.3 2.3–2.3ROR 2.4 · calibrated p 0.860 | 2.3 EB05 2.2 · IC025 +1.2 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 1.9 · serious PRR 2.6 | no trial arm names this drug |
| Toxicity to various agents | 15,844 | 8.5 8.4–8.7ROR 9.0 · calibrated p 0.045 ✓ | 7.8 EB05 7.7 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | age-adj. PRR 6.6 · serious PRR 5.1 · 96% clinician | no trial arm names this drug |
| Dyspnoea (shortness of breath) | 15,013 | 2.2 2.2–2.3ROR 2.3 · calibrated p 0.901 | 2.2 EB05 2.2 · IC025 +1.1 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 1.8 · serious PRR 1.9 | no trial arm names this drug |
| Pyrexia (fever) | 14,573 | 3.6 3.5–3.6ROR 3.7 · calibrated p 0.428 | 3.5 EB05 3.4 · IC025 +1.8 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.8 · serious PRR 2.7 | no trial arm names this drug |
| Arthralgia (joint pain) | 14,570 | 3.0 2.9–3.0ROR 3.1 · calibrated p 0.595 | 2.9 EB05 2.9 · IC025 +1.5 3/3 methods agree | Not in label — unassessed | age-adj. PRR 2.3 · serious PRR 3.3 · ♀ 85% (drug 62%) | no trial arm names this drug |
| Vomiting | 14,469 | 2.6 2.6–2.6ROR 2.7 · calibrated p 0.733 | 2.6 EB05 2.5 · IC025 +1.3 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.3 · serious PRR 2.4 | no trial arm names this drug |
| Diarrhoea (diarrhea) | 13,719 | 1.8 1.8–1.8ROR 1.8 · calibrated p 0.845 | 1.8 EB05 1.7 · IC025 +0.8 | Labeled adverse reaction exact term | age-adj. PRR 1.6 · serious PRR 1.8 | no trial arm names this drug |
| Rash | 12,690 | 2.5 2.4–2.5ROR 2.5 · calibrated p 0.796 | 2.4 EB05 2.4 · IC025 +1.2 3/3 methods agree | Labeled — boxed warning exact term | age-adj. PRR 2.2 · serious PRR 3.2 · ♀ 82% (drug 62%) | no trial arm names this drug |
| Pneumonia (lung infection) | 11,271 | 3.0 2.9–3.0ROR 3.0 · calibrated p 0.612 | 2.9 EB05 2.8 · IC025 +1.5 3/3 methods agree | Not in label — unassessed | age-adj. PRR 2.5 · serious PRR 2.0 | no trial arm names this drug |
| Infusion related reaction (reaction during infusion) | 11,177 | 16.7 16.3–17.0ROR 17.4 · calibrated p 0.004 ✓ | 14.0 EB05 13.8 · IC025 +3.8 3/3 methods agree | Not in label — unassessed | age-adj. PRR 12.7 · serious PRR 10.9 · ♀ 84% (drug 62%) | no trial arm names this drug |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Pyroglutamic acidosis — n=287, PRR 262.8
- Vaginal flatulence — n=223, PRR 227.5
- Appendicolith — n=276, PRR 224.7
- Rheumatic fever — n=2,684, PRR 132.9
- Deep vein thrombosis postoperative — n=1,180, PRR 125.8
- Duodenal ulcer perforation — n=4,404, PRR 124.9
- Lupus vulgaris — n=689, PRR 114.3
- Exposure to toxic agent — n=1,696, PRR 92.1
- Facet joint syndrome — n=1,632, PRR 88.9
- Helicobacter infection — n=4,470, PRR 64.4
✓ A hand-written Bradford Hill causality assessment exists for this drug: Acetaminophen (paracetamol) ↔ Liver injury / hepatotoxicity.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Acetaminophen Tablet Extended Release?
In FDA FAERS, the most frequently co-reported reaction terms for Acetaminophen Tablet Extended Release are fatigue, pain, nausea, headache, toxicity to various agents, dyspnoea. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Acetaminophen Tablet Extended Release have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: RISK OF MEDICATION ERRORS AND HEPATOTOXICITY Take care when prescribing, preparing, and administering acetaminophen injection to avoid dosing errors which could result in accidental overdose and death. In particular,.
Do FAERS signals prove that Acetaminophen Tablet Extended Release causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 0f67c1bd-915b-4681-88dd-22f5154a80b3, effective 20240506; matched on
openfda.generic_name.exact:"ACETAMINOPHEN" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG") - PubChem CID 1983 description (ChEBI)
- Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,202 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
ACETAMINOPHEN, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.